Femasys Gains Nasdaq Extension to Avoid Delisting
Event summary
- Femasys received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement.
- The extension, granted January 13, 2026, provides until July 13, 2026, to achieve compliance.
- Nasdaq’s decision was contingent on Femasys meeting other listing requirements and indicating a potential reverse stock split.
- Compliance will be triggered if the share price closes above $1.00 for ten consecutive business days.
The big picture
Femasys's Nasdaq compliance issue highlights the challenges faced by smaller, growth-stage biomedical companies reliant on capital markets. The extension provides a temporary reprieve, but the underlying problem – a depressed share price – reflects concerns about the company's commercial execution and the long timelines inherent in bringing innovative medical products to market. The potential for a reverse stock split introduces further uncertainty for investors.
What we're watching
- Reverse Split
- The company's stated intention to consider a reverse stock split signals a potential willingness to take drastic measures to maintain Nasdaq listing, which could negatively impact existing shareholders.
- Share Price
- The ability of Femasys to sustain a share price above $1.00 will depend on market sentiment and the successful commercialization of its fertility and birth control products, particularly FemBloc in international markets.
- FDA Approval
- The ongoing FINALE trial for FemBloc’s U.S. FDA approval is critical; a positive outcome would likely boost investor confidence and the share price, but delays or setbacks could further exacerbate the compliance issue.
Related topics